Actively Recruiting
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Led by University of Louisville · Updated on 2025-10-29
10
Participants Needed
1
Research Sites
606 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
CONDITIONS
Official Title
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Diagnosed with stage III pancreatic cancer
- Tumor is measurable
- Glomerular filtration rate greater than 60 mL/min/1.73 m²
- Willing and able to follow the study protocol
- Able to understand and sign informed consent
You will not qualify if you...
- Currently participating in another clinical trial for cancer treatment
- Pregnant or breastfeeding
- Have a cardiac pacemaker or implantable cardioverter defibrillator that cannot be turned off during the procedure
- Have non-removable metal implants within 1 cm of the target tumor
- Had a heart attack within 3 months before joining the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Louisville
Louisville, Kentucky, United States, 40202
Actively Recruiting
Research Team
R
Robert Martin, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here